Corcept Therapeutics (CORT)

$79.91 -1.84 (-2.25%)
Market Cap 8.58B
Revenue (ttm) 761.41M
Net Income (ttm) 99.65M
EPS (ttm) N/A
PE Ratio 233.57
Forward PE 153.52
Profit Margin 13.09%
Debt to Equity Ratio 0.00
Volume 1,875,500
Avg Vol 1,105,358
Day's Range N/A - N/A
Shares Out 107.35M
Stochastic %K 57%
Beta 0.50
Analysts Strong Sell
Price Target $88.00

Company Profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery....

Industry: Biotechnology
Sector: Healthcare
Phone: 650 327 3270
Address:
101 Redwood Shores Parkway, Redwood City, United States
gucag006
gucag006 Jun. 19 at 4:19 AM
$CORT I asked Gemini Pro about the last after-hours trade at 7:53pm EST. The AI found it. But when I askef for the # of shares traded, AI said it was a mistake before and there was no such trade. I asked again below:
0 · Reply
moorenard1
moorenard1 Jun. 18 at 4:12 PM
$CORT 6 months ago to the day CORT was $81.52. Today it is basically the same price. Here are some key differences between now and 6 montsh ago: 6 Months ago: Cort had no oncology business - shorts said Rela would never get approved Today: Approved drug that can work in multiple cancer types. Early sales trajectory blowing estimates out of water. Likely to be a $4 billion/yr platform. 6 months ago: annual Korlym sales: $760MM Today: This year projected to be $1 billion roughly 30% higher 6 months ago: FDA was run by folks who were rejecting everything as policy Today: Relacorilant will be submitted by end of year with more compelling package and much friendlier FDA 6 months ago: MASH data a year out Today: MASH data 6 months away 6 months ago: Shorts time to cover 3.04 days Today: Shorts time to cover 8.54 days
2 · Reply
gucag006
gucag006 Jun. 18 at 5:55 AM
$CORT Good Job, Dr. Belanoff! You and your staff never disappointed me.
0 · Reply
AXLFI_HQ
AXLFI_HQ Jun. 17 at 10:54 PM
$CORT FDA regulatory approvals are expanding for healthcare innovations in glucose monitoring and psychiatric treatments, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
jsmith5788
jsmith5788 Jun. 17 at 8:31 PM
$CORT https://ir.corcept.com/news-releases/news-release-details/corcept-resubmits-new-drug-application-relacorilant-treatment
0 · Reply
gucag006
gucag006 Jun. 16 at 6:31 PM
$CORT 6-mo SP chart - We're fully recovered from last Dec drop, and where we're going, watch out shorties, to the Moon then to the Mars!
1 · Reply
gucag006
gucag006 Jun. 15 at 8:23 PM
$CORT Not only we have Korlyhm (CS), Liyorli (PROC), Relacorilant (CS), Dazucorilant (ALS), Miricorilant (MASH), Nenocorilant (Solid Tumors) as blockbuster compounds/drugs, don't forget we also have quite a few SP-catapulting short-term catalysts: 1. Relacorilant (OS) NDA resubmission - any days now, 2. Liyorli (PROC) subscriptions and sales update - Aug/26 3. CORT ER (rev/sales/profits/clinical updaes) - Aug/26, Nov/26 4. Dazucorilant (ALS) P3 trial initiation - H2/26, 5. Relacorilant (OS) FDA nod - late Q4/26 or early Q1/27 6. Miricorilant (MASH) P2b trial started in 2023, enrollment completed in late 2025, 48-wk treatment cycle, projected completion date late 2026, data readout in H1/27, P3 starts in H2/27 Each of these ST catalysts will catapult the SP to new ATH's. Cheer & GLTA!
1 · Reply
Orbit100
Orbit100 Jun. 15 at 6:41 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:41 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:40 PM
$CORT
0 · Reply
Latest News on CORT
Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

2026-06-17T20:30:11.000Z - 2 days ago

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

Jun 17, 2026, 4:28 PM EDT - 2 days ago

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

Corcept announces presentation of new data from Catalyst, Momentum trials

2026-06-07T22:05:06.000Z - 12 days ago

Corcept announces presentation of new data from Catalyst, Momentum trials

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

May 29, 2026, 4:33 PM EDT - 21 days ago

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

2026-05-28T12:08:48.000Z - 22 days ago

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright

2026-05-28T10:10:27.000Z - 22 days ago

Corcept Therapeutics price target raised to $95 from $75 at H.C. Wainwright

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

2026-05-27T14:36:43.000Z - 23 days ago

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

May 27, 2026, 8:00 AM EDT - 23 days ago

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2026-05-13T13:38:36.000Z - 5 weeks ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

Corcept Therapeutics upgraded to Buy from Neutral at UBS

2026-05-13T09:35:12.000Z - 5 weeks ago

Corcept Therapeutics upgraded to Buy from Neutral at UBS

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

2026-05-04T10:17:31.000Z - 6 weeks ago

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

2026-05-01T11:37:49.000Z - 7 weeks ago

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

2026-04-30T21:06:37.000Z - 7 weeks ago

Corcept Therapeutics announced 2-year OS data from Phase 2 dazucorilant study

Corcept Therapeutics Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Corcept Therapeutics Earnings Call Transcript: Q1 2026

Corcept Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Corcept Therapeutics Earnings release: Q1 2026

Corcept Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 7 weeks ago

Corcept Therapeutics Quarterly report: Q1 2026

Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)

2026-04-30T20:28:44.000Z - 7 weeks ago

Corcept Therapeutics reports Q1 EPS (30c), consensus (14c)

Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M

2026-04-30T20:28:17.000Z - 7 weeks ago

Corcept Therapeutics raises FY26 revenue view to $950M-$1.05B, consensus $933.2M

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Apr 30, 2026, 4:05 PM EDT - 7 weeks ago

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Apr 30, 2026, 4:05 PM EDT - 7 weeks ago

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Apr 23, 2026, 4:05 PM EDT - 2 months ago

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Apr 21, 2026, 1:09 PM EDT - 2 months ago

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

Corcept Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Corcept Therapeutics Proxy statement: Proxy filing

Corcept Therapeutics presents final overall survival data from ROSELLA trial

2026-04-10T20:56:08.000Z - 2 months ago

Corcept Therapeutics presents final overall survival data from ROSELLA trial

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Apr 10, 2026, 4:45 PM EDT - 2 months ago

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

2026-04-02T09:40:29.000Z - 2 months ago

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

Corcept Therapeutics presents data from Momentum trial at ACC 2026

2026-03-29T14:55:40.000Z - 2 months ago

Corcept Therapeutics presents data from Momentum trial at ACC 2026

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Mar 28, 2026, 2:45 PM EDT - 2 months ago

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research

2026-03-26T12:50:58.000Z - 3 months ago

Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

2026-03-26T11:17:59.000Z - 3 months ago

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

2026-03-25T18:25:15.000Z - 3 months ago

Corcept Therapeutics price target raised to $110 from $100 at Canaccord

Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer

Mar 25, 2026, 1:18 PM EDT - 3 months ago

Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer

Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer

2026-03-25T16:50:44.000Z - 3 months ago

Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer

FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Mar 25, 2026, 12:43 PM EDT - 3 months ago

FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Mar 18, 2026, 5:35 PM EDT - 3 months ago

Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 11, 2026, 4:48 PM EDT - 3 months ago

Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

Mar 10, 2026, 6:00 PM EDT - 3 months ago

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

Corcept Therapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

Corcept Therapeutics Earnings Call Transcript: Q4 2025

Corcept Therapeutics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

Corcept Therapeutics Annual report: Q4 2025

Corcept Therapeutics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

Corcept Therapeutics Earnings release: Q4 2025

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Feb 24, 2026, 4:05 PM EST - 4 months ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Feb 19, 2026, 4:00 PM EST - 4 months ago

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Feb 17, 2026, 4:05 PM EST - 4 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Feb 9, 2026, 4:54 AM EST - 4 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 2:20 PM EST - 5 months ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 30, 2026, 10:36 AM EST - 5 months ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:13 AM EST - 5 months ago

Corcept's cancer drug meets main goal in late-stage trial

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 22, 2026, 8:00 AM EST - 5 months ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

These under-the-radar stocks combine fast growth with big upside potential

Jan 15, 2026, 10:31 AM EST - 5 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Jan 14, 2026, 9:52 PM EST - 5 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

gucag006
gucag006 Jun. 19 at 4:19 AM
$CORT I asked Gemini Pro about the last after-hours trade at 7:53pm EST. The AI found it. But when I askef for the # of shares traded, AI said it was a mistake before and there was no such trade. I asked again below:
0 · Reply
moorenard1
moorenard1 Jun. 18 at 4:12 PM
$CORT 6 months ago to the day CORT was $81.52. Today it is basically the same price. Here are some key differences between now and 6 montsh ago: 6 Months ago: Cort had no oncology business - shorts said Rela would never get approved Today: Approved drug that can work in multiple cancer types. Early sales trajectory blowing estimates out of water. Likely to be a $4 billion/yr platform. 6 months ago: annual Korlym sales: $760MM Today: This year projected to be $1 billion roughly 30% higher 6 months ago: FDA was run by folks who were rejecting everything as policy Today: Relacorilant will be submitted by end of year with more compelling package and much friendlier FDA 6 months ago: MASH data a year out Today: MASH data 6 months away 6 months ago: Shorts time to cover 3.04 days Today: Shorts time to cover 8.54 days
2 · Reply
gucag006
gucag006 Jun. 18 at 5:55 AM
$CORT Good Job, Dr. Belanoff! You and your staff never disappointed me.
0 · Reply
AXLFI_HQ
AXLFI_HQ Jun. 17 at 10:54 PM
$CORT FDA regulatory approvals are expanding for healthcare innovations in glucose monitoring and psychiatric treatments, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
jsmith5788
jsmith5788 Jun. 17 at 8:31 PM
$CORT https://ir.corcept.com/news-releases/news-release-details/corcept-resubmits-new-drug-application-relacorilant-treatment
0 · Reply
gucag006
gucag006 Jun. 16 at 6:31 PM
$CORT 6-mo SP chart - We're fully recovered from last Dec drop, and where we're going, watch out shorties, to the Moon then to the Mars!
1 · Reply
gucag006
gucag006 Jun. 15 at 8:23 PM
$CORT Not only we have Korlyhm (CS), Liyorli (PROC), Relacorilant (CS), Dazucorilant (ALS), Miricorilant (MASH), Nenocorilant (Solid Tumors) as blockbuster compounds/drugs, don't forget we also have quite a few SP-catapulting short-term catalysts: 1. Relacorilant (OS) NDA resubmission - any days now, 2. Liyorli (PROC) subscriptions and sales update - Aug/26 3. CORT ER (rev/sales/profits/clinical updaes) - Aug/26, Nov/26 4. Dazucorilant (ALS) P3 trial initiation - H2/26, 5. Relacorilant (OS) FDA nod - late Q4/26 or early Q1/27 6. Miricorilant (MASH) P2b trial started in 2023, enrollment completed in late 2025, 48-wk treatment cycle, projected completion date late 2026, data readout in H1/27, P3 starts in H2/27 Each of these ST catalysts will catapult the SP to new ATH's. Cheer & GLTA!
1 · Reply
Orbit100
Orbit100 Jun. 15 at 6:41 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:41 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:40 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:40 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:40 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:15 PM
$CORT Yahoo Finance has Corcept target price between $110 to $135.
0 · Reply
Orbit100
Orbit100 Jun. 15 at 6:15 PM
$CORT Analyst Canaccord Genuity Rating Action Maintains Rating Buy Price Action Raises Price Target 110 -> 135
0 · Reply
Orbit100
Orbit100 Jun. 15 at 5:37 PM
$CORT Interesting fast recovery from under $80 to be over $83 by people buying up the cheap shares.
0 · Reply
Orbit100
Orbit100 Jun. 15 at 4:35 PM
$CORT Someone on this board issued a perfect right call of the beginning of short squeeze this early a.m. This is the beginning of huge zoom up for the stock price. Heed the warning.
0 · Reply
forprofit12
forprofit12 Jun. 15 at 3:33 PM
$CORT added some more.
0 · Reply
Orbit100
Orbit100 Jun. 15 at 2:12 PM
$CORT Corcept was traded at $85 at Pre Market this morning when I checked at 5 am. Some weak hand got lurced to sell. Time to reload and add more.
1 · Reply
Orbit100
Orbit100 Jun. 15 at 2:05 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 2:04 PM
$CORT
0 · Reply
Orbit100
Orbit100 Jun. 15 at 2:03 PM
$CORT
0 · Reply
moorenard1
moorenard1 Jun. 15 at 1:52 PM
$CORT SHORT SQUEEZE INCOMING As the shorts try to wriggle out of their horrendous bet against CORT, the numbers are working against them. Their total liability is approaching $1 Billion, yet between mid and late May, their time to cover increased nearly 50%. A quick squeeze could pop stock well over $100 and then gap up to $150. These guys have to buy nearly $1 billion in stock!
0 · Reply